[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"st-elevation-myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:st-elevation-myocardial-infarction":146},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,48,74,104,129,163,187,221,244,270,298,325,354,377,404,429,455,480,505,530,556,577,599,624,647],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642956","coronary-thrombus-modification-to-prevent-microvascular-damage-in-patients-with-st-segment-elevation-myocardial-infarction-the-cormi-trial-100642956",false,"NCT07646977","CORonary Thrombus Modification to Prevent MIcrovascular Damage in Patients With ST-segment Elevation Myocardial Infarction (The CORMI Trial)","Inclusion Criteria:\n\n* ST-elevation at the J-junction in a minimum of two contiguous ECG leads with a minimum of ≥ 0.1 mV in all leads, except for V2 and V3 (which required ≥ 0.2 for men ≥ 40 years old, ≥ 0.25 in men \\\u003C 40 years old, or ≥ 0.15 mV for all women) or new left bundle branch\n* Admission to hospital within 12 hours of symptom debut\n* Angiographic signs of a culprit lesion planned to be treated with primary percutaneous coronary intervention\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years or inability to provide informed consent\n* Life expectancy of \\\u003C 12 months\n* Hemodynamically instability\n* Pregnancy or breastfeeding\n* Known asthma or severe chronic obstructive pulmonary disease\n* Expected inability to perform physiological measurements (due to severely tortuous arteries, ostial disease or very distal disease),\n* CMR contraindications (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin, magnetic or mechanically activated implants, or any prior metal implants, severe claustrophobia)\n* Expected to or unavoidable to use thrombectomy","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to evaluate the effects of coronary thrombus modification on preventing the microvascular damage associated with primary percutaneous coronary intervention (PCI), and to limit the associated myocardial damage assessed by myocardial salvage index after 3 months. Furthermore, the project will evaluate coronary microvascular damage assessed invasively using both continuous and bolus thermodilution before and after stent implantation. In addition, the project will evaluate the diagnostic ability and associations of pre-stenting invasive physiological measurement to cardiac magnetic resonance imaging measurements.",[26,27,28],"ST Elevation Myocardial Infarction","Coronary Microvascular Dysfunction","Percutaneous Coronary Intervention",[30,31,32,33,34],"Microvascular damage","Continuous thermodilution","Bolus thermodilution","Myocardial damage","Cardiac MRI","NOT_YET_RECRUITING","2026-06-19",{"date":38,"type":39},"2026-06-24","ACTUAL",{"date":41,"type":20},"2026-06",{"date":43,"type":20},"2034-01",{"name":45,"class":46},"Odense University Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100543263","reduced-stent-strategy-versus-conventional-percutaneous-coronary-revascularization-in-patients-presenting-with-stemi-100543263","NCT06353594","Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI","Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With St-segment Elevation Myocardial Infarction (Copernican)","COPERNICAN","Inclusion Criteria:\n\n\\- Patients presenting with STEMI and indication to undergo pPCI.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year due 1 to non-cardiac disease.\n* Inability to provide informed consent.\n* Cardiogenic shock.\n* Left ventricular ejection fraction \\\u003C15%.\n* Left main disease.\n* Stent thrombosis\n* Patients with prior bypass graft lesions requiring PCI (culprit or non culprit lesions).\n* Patients with chronic total occlusions.\n* Untreatable coronary disease.\n* Non-identified culprit lesion.\n* Known allergy to aspirin, ticagrelor, prasugrel, clopidogrel, paclitaxel or sirolimus.",{"count":57,"type":20},1272,[23],"The objective is to compare a reduced stent strategy based on drug-coated balloon (DCB) percutaneous coronary intervention (PCI) with conventional drug-eluting stent (DES) coronary revascularization in patients presenting with ST-segment myocardial infarction (STEMI).\n\nRandomization will be performed after successful culprit-lesion guidewire crossing and flow restoration. Random allocation in a 1:1 fashion to one of the following strategies:\n\n* Study group: reduced stent PCI strategy (DCB-based)\n* Control group: conventional PCI strategy (DES-based).",[26],[62],"STEMI","RECRUITING","2026-05-25",{"date":66,"type":39},"2026-05-28",{"date":68,"type":39},"2024-03-11",{"date":70,"type":20},"2035-09",{"name":72,"class":46},"Hospital Universitario La Fe",23,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":16,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100533587","oct-versus-angiography-for-culprit-lesion-revascularization-in-acute-myocardial-infarction-patients-100533587","NCT06227754","OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts","Randomized Controlled Trial of Optical Coherence Tomography Versus Angiography for Culprit Lesion Revascularization in Patients With Acute Myocardial Infarction","FRAME-AMI3","Inclusion Criteria:\n\n* Subject must be at least 19 years of age\n* Acute ST-segment elevation myocardial infarction (STEMI)\n\n  \\*STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1\n* Primary percutaneous coronary intervention (PCI) in \\\u003C 12 h after the onset of symptoms for STEMI patients\n* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Target lesions not amenable for PCI by operators' decision\n* Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's discretion)\n* Creatinine clearance ≤30 ml\u002Fmin\u002F1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance)\n* Cardiogenic shock (Killip class IV) at presentation\n* Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus\n* Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)\n* Pregnancy or breast feeding\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C2 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n* Unwillingness or inability to comply with the procedures described in this protocol","19 Years",{"count":84,"type":20},1500,[23],"The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).",[26,88],"Myocardial Infarction",[90,91,92,93],"ST-segment elevation MI","Optical coherence tomography","Intravascular imaging","Primary PCI","2026-05-05",{"date":96,"type":39},"2026-05-08",{"date":98,"type":39},"2024-03-25",{"date":100,"type":20},"2031-12-31",{"name":102,"class":46},"Chonnam National University Hospital",18,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":47},"100422060","stemi-treatment-optimization-by-ischemic-postconditioning-and-ivus-guidance-100422060","NCT04775914","STEMI Treatment Optimization by Ischemic Postconditioning and IVUS Guidance","The STEMI Optimization Trial - Ischemic Postconditioning (DANAMI4-iPOST) and Intravascular Ultrasound Guided PCI in STEMI (DANAMI4-iSTEMI)","DANAMI4","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute onset of chest pain with \\\u003C12 hours duration\n* STEMI as characterized by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with minimum of 1 mm concordant ST elevation or 1 mV ST-segment elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior AMI.\n\nExclusion Criteria (iPOST2):\n\nPre-PCI TIMI flow 0 or 1 Potential pregnancy Inability to provide informed consent Unwillingness to consent Unavoidable to use thrombectomy Spontaneous coronary artery dissection Time from symptoms onset to PPCI \\> 12 hours Culprit in bypass graft Other reason for not including the patient\n\nExclusion Criteria (iSTEMI):\n\nPotential pregnancy Inability to understand information in order to provide informed consent Unwillingness to consent Spontaneous coronary artery dissection Time from symptoms inset to PPCI \\> 12 hours Culprit in bypass graft Other reason",{"count":113,"type":20},2500,[23],"The purpose of is study is to investigate whether ischemic postconditioning (iPOST) and intravascular ultrasound-guided (IVUS) percutaneous coronary intervention (PCI) improve the clinical outcome of patients with ST-segment elevation myocardial infarction treated with primary PCI.",[26],[93,118,119],"Coronary angiography","Intravascular ultra sound (IVUS)","2026-03-24",{"date":122,"type":39},"2026-03-30",{"date":124,"type":39},"2021-04-01",{"date":126,"type":20},"2031-02-01",{"name":128,"class":46},"Thomas Engstrom",{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":148,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":47},"100627155","safety-and-effectiveness-of-the-crystalline-sirolimus-eluting-device-in-patients-with-coronary-artery-disease-100627155","NCT07444957","Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease","Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device (SeQuent® Sirolimus-Coated Balloon) in Patients With Coronary Artery Disease: A Prospective Observational Study","SECuRE","Inclusion Criteria:\n\n* All patients must provide written informed consent.\n* Patients aged ≥18 years with coronary artery disease in whom, at the operator's discretion, treatment of a coronary stenosis in a native vessel (either de novo lesion or in-stent restenosis) or in a coronary bypass graft using the cSCB is indicated, in accordance with routine clinical practice.\n* All treated lesions\u002Fsegments (single or tandem) must receive cSCB therapy covering at least 3 mm beyond both edges of the lesion or pre-dilated segment to avoid geographic miss.\n* In patients with multivessel coronary artery disease, all non-target vessels will be treated according to operator discretion: a) If more than one vessel is treated with the investigational device (SeQuent® SCB), all vessels will be documented and analyzed separately. b) Only one lesion per vessel will be included unless lesions are separated by ≥20 mm. c) Only one lesion per vessel will be included. d) If more than one lesion in the target vessel requires treatment, all lesions treated with a device different from the investigational procedure or with a device other than the investigational device (SeQuent® SCB) must be separated from the target lesion by ≥20 mm or considered as a single treated lesion according to this study protocol.\n\nExclusion Criteria:\n\n* Explicit refusal by the patient to participate in the study.\n* Known intolerance to sirolimus or to any component of the investigational device.\n* Contraindication to any antiplatelet therapy.\n* Life expectancy less than 12 months.\n* Indication for surgical coronary revascularization.\n* Pregnancy or breastfeeding.\n* Clinical characteristics considered unsuitable for drug-coated balloon use at the operator's discretion, including: a) Hemorrhagic diathesis or other conditions such as gastrointestinal ulceration or cerebrovascular disorders restricting the use of antiplatelet therapy. b) Cardiogenic shock. c) Patients with left ventricular ejection fraction \\\u003C30% without the use of a ventricular assist device during PCI.\n\nAngiographic exclusion criteria\n\n* Reference vessel diameter \\\u003C2.00 mm or \\>4.0 mm.\n* Treatment of the left main coronary artery.\n* Lesions not amenable to PCI or other interventional techniques.\n* Coronary artery spasm in the absence of significant stenosis.\n* Target lesion not suitable for drug-coated balloon-only PCI at the operator's discretion, including: a) Aorto-ostial lesions. b) Lesions with significant persistent residual thrombotic content visible in the vessel despite thromboaspiration. c) Treatment shortly after myocardial infarction with evidence of thrombus or impaired coronary flow.",{"count":138,"type":20},1118,"OBSERVATIONAL","This prospective, multicenter, post-market observational study aims to evaluate the safety and effectiveness of the crystalline sirolimus-coated balloon (SeQuent® Sirolimus-Coated Balloon) for the treatment of coronary artery disease in routine clinical practice. Consecutive, unselected adult patients undergoing percutaneous coronary intervention for de novo coronary lesions or in-stent restenosis will be enrolled.\n\nThe primary objective is to assess target lesion failure at 12 months, defined as the composite of target vessel myocardial infarction or ischemia-driven target lesion revascularization. Secondary objectives include angiographic procedural success, major adverse cardiovascular events, bleeding outcomes, and longer-term clinical results up to 36 months, as well as outcomes across predefined anatomical and clinical subgroups.\n\nThe study seeks to answer whether treatment with the crystalline sirolimus-coated balloon provides a safe and effective revascularization strategy in a real-world population with diverse clinical presentations and lesion characteristics.",[142,143,144,145,146,147],"Coronary Arterial Disease (CAD)","NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","Stable Angina, Unstable Angina, NSTEMI","Drug Coated Balloon","ST-Elevation Myocardial Infarction","Silent Ischemia",[149,150,151,152,153],"coronary arterial disease","drug coated ballloon","TLR","TVR","MACE","2026-03-02",{"date":156,"type":39},"2026-03-03",{"date":158,"type":39},"2026-01-05",{"date":160,"type":20},"2030-07-06",{"name":162,"class":46},"Fundación Interhospitalaria para la Investigación Cardiovascular FIC",{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":16,"minAge":170,"maxAge":4,"enrollmentInfo":171,"targetDuration":173,"studyType":139,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100519206","early-discharge-pathway-registry-100519206","NCT06040528","Early Discharge Pathway Registry","Barts Early Post-Acute Myocardial Infarction Discharge Registry","Inclusion Criteria:\n\nInformed consent will not be sought for, as patients are automatically included onto a database that we will use for research purposes. No children will be included in this study. Vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the Interventional Cardiology team.\n\nBoth male and female patients ≥16 years of age will be included\n\nAll patients will have been admitted to BHC with acute coronary syndrome.\n\nExclusion Criteria:\n\nPatients \\\u003C16 years will not be included in this study.","16 Years",{"count":172,"type":20},20000,"12 Months","Despite the year-on-year decrease, coronary artery disease (CAD) still remains one of the leading causes of mortality worldwide. With advances in technology and our understanding of cardiac disease, we can now treat CAD using minimally invasive interventional techniques. This has revolutionised treatment for and improved the lives of many patients with CAD. Although trials have assessed various therapeutic strategies in various populations, real-world evidence of intervention and medical treatment among patients with CAD is increasingly recognised as an important part of providing safety and efficacy data and improving the care we provide.\n\nRegional heart attack services have improved clinical outcomes following ST-segment elevation myocardial infarction (STEMI) by facilitating early reperfusion by primary percutaneous coronary intervention (PCI). Early discharge after primary PCI is welcomed by patients and increases the efficiency of health care.\n\nThis data will add to that literature by assessing the characteristics and outcomes of patients with CAD, concentrating on those who are discharged via the early discharge pathway. It will also identify and characterise predictors of outcomes, and improve risk stratification and diagnostic evaluation.",[88,26,176],"Non-ST Elevation Myocardial Infarction","2026-02-26",{"date":179,"type":39},"2026-02-27",{"date":181,"type":39},"2023-11-11",{"date":183,"type":20},"2026-12-31",{"name":185,"class":46},"Queen Mary University of London",2,{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":197,"studyType":139,"phases":4,"briefSummary":198,"conditions":199,"keywords":203,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":47},"100626499","drug-coated-balloon-primary-pci-in-st-segment-elevation-myocardial-infarction-100626499","NCT07436429","Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction","Drug Coated Balloon-Based Primary PCI in ST-segment Elevation Myocardial Infarction - The DCB-STEMI Multicenter Registry","DCB-STEMI","Inclusion Criteria:\n\n* All ST-elevation MI undergoing Primary PCI\n\nExclusion Criteria:\n\n* In-stent culprit lesion\n* Contraindications to antiplatelets\n* Stent implantation within 3 months before enrollment\n* Cardiac arrest, intubation, or cardiogenic shock\n* Life-expectancy less than one year",{"count":196,"type":20},300,"30 Days","Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority over thrombolysis, plain balloon angioplasty, and bare-metal stents. Recently, the use of drug-coated balloons (DCB) has expanded dramatically across a variety of anatomical and clinical settings, including de novo coronary lesions. A DCB-based pPCI strategy may simplify the procedure and mitigate the risks of inadequate stent sizing due to spasm or large thrombus burden, acute stent thrombosis, distal embolization, no reflow, and the relatively higher incidence of late stent-related adverse events compared with elective PCI. Despite these theoretical advantages, data on the safety and efficacy of DCB-based pPCI in STEMI remains limited.\n\nThe aim of this registry is to explore procedural and clinical outcomes of patients with STEMI treated with a DCB-based pPCI strategy.",[200,146,62,201,202],"Myocardial Infarction (MI)","STEMI (STE-ACS)","Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)",[204,205,206,207,208,209,210,211,212],"Drug-coated balloon","Primary percutaneous coronary intervention","De novo coronary lesion","Limus-coated balloon","Paclitaxel-coated balloon","Net adverse clinical events","Bleeding Academic Research Consortium bleeding","ST-segment elevation myocardial infarction","Drug-Eluting Balloon","2026-02-22",{"date":179,"type":39},{"date":216,"type":39},"2026-02-08",{"date":218,"type":20},"2026-07-01",{"name":220,"class":46},"Medical University of Vienna",{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":231,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":47},"100529513","phase-3-dapagliflozin-in-stemi-100529513","NCT06174753","Dapagliflozin in STEMI","The University of Ottawa Dapagliflozin in STEMI Randomized Clinical Trial","DAPA STEMI","Inclusion Criteria:\n\nPatients referred for PPCI meeting the following criteria are eligible for the study:\n\n* Ischemic chest discomfort of ≥30 minutes duration, and\n* Onset of chest pain ≤12 hours prior to entry into the study, and\n* One of the following High-Risk criteria on a standard 12 lead ECG:\n\n  a. Anterior STEMI with ST-segment elevation ≥2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6) b. Extensive non-anterior STEMI defined as ST-segment elevation of \\>1mm in two or more contiguous non-anterior leads accompanied by i. 8 or more leads with \\> 1 mm ST elevation or depression, or both; OR ii. Sum of ST- segment elevation \\>20mm\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Any contraindication to undergo CMR imaging\n* Killip 4 (Cardiogenic shock on presentation)\n* Therapy with SGLT2i within last 8 weeks\n* Type 1 diabetes mellitus\n* Pregnancy\n* Nursing mother\n* Unwilling to use appropriate forms of contraception, as applicable\n* Chronic symptomatic HF with prior hospitalization for HF within the last year\n* hospitalization\n* Known history of prior MI\n* Any non-CV condition with a life expectancy of less than one year\n* Previous randomization in the present study\n* Participation in a study with another investigational device or drug \\\u003C four weeks\n* Inability to provide informed consent\n* Confirmed ketoacidosis at time of admission\n* Known severe hepatic impairment (Cirrhosis)\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin1.73m2 (based on prior or baseline blood work)\n* Known severe valvular heart disease\n* Need for CABG within 90 days based on the results of the initial coronary angiogram\n* False positive STEMI (based on the results of the coronary angiogram)",{"count":230,"type":20},256,[232],"PHASE3","The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI.\n\nEligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo.\n\nCardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.",[26,88],"2026-02-18",{"date":237,"type":39},"2026-02-20",{"date":239,"type":39},"2025-01-20",{"date":241,"type":20},"2027-12",{"name":243,"class":46},"Ottawa Heart Institute Research Corporation",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":21,"phases":254,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":186},"100499641","stemi-treated-with-a-polymer-free-sirolimus-coated-stent-and-p2y12-inhibitor-based-sapt-versus-conventional-dapt-100499641","NCT05785897","STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","ST-segment Elevation Myocardial infArction Treated With a Polymer-free Sirolimus-based nanocarrieR Eluting Stent and a P2Y12 Inhibitor-based Aspirin-free Single Antiplatelet Strategy Versus Conventional Dual AntiPlatelet Therapy","STARS DAPT","Inclusion criteria\n\n* Age ≥18 years.\n* Subjects who have received DAPT consisting of aspirin and any of the commercially available P2Y12 receptor inhibitors (ticagrelor, prasugrel, or clopidogrel) at the time of STEMI diagnosis, or at the very latest at the time of primary PCI.\n* Subjects with ≥1 acute infarct artery target vessel with ≥1 coronary artery stenosis in a native coronary artery with diameter from 2.25 to 4.0 mm who underwent successful primary PCI, defined as primary PCI with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation, and final residual stenosis \\\u003C30% by visual estimation or 20% by quantitative coronary angiography (QCA) \\[38\\].\n* Subject willing to participate and able to understand, read and sign the informed consent form.\n\nExclusion criteria:\n\n* Known allergy or intolerance to aspirin, ticagrelor, prasugrel, or sirolimus.\n* Inability to adhere to DAPT for at least 6 months.\n* Patient already on DAPT at index presentation due to recent PCI for chronic coronary syndrome (\\\u003C6 months) or ACS (\\\u003C12 months).\n* Patient on chronic oral anticoagulation at index presentation.\n* Patient with mechanical complication of STEMI.\n* Patient with STEMI due to stent thrombosis.\n* Planned non-cardiac surgery that cannot be postponed for at least 6 months.\n* Participation or planned participation in another interventional clinical trial.\n* Life expectancy \\\u003C1 years.\n* Pregnancy.\n* Unwillingness or inability (e.g. physical or cognitive) to comply with study procedure, medication adherence and schedule.",{"count":253,"type":20},350,[23],"Primary percutaneous coronary intervention (PCI) is the preferred revascularization strategy for patients with acute ST-segment elevation myocardial infarction (STEMI). Compared with bare-metal stents (BMS) and early-generation thick-strut polymer-based drug-eluting stents (DES), newer-generation DES with thinner strut stent platforms and durable or biodegradable polymers have been shown to improve long-term safety and efficacy outcomes among patients with STEMI. Accordingly, the use of newer-generation DES over BMS is currently recommended by the most recent guidelines. Vessel healing at the culprit site after DES implantation is however substantially delayed in patients with acute STEMI as compared to those with chronic coronary syndromes and is associated with a long-term risk for recurrent stent-related adverse clinical outcomes. These findings highlight the need for future iterations in modern DES technology to further improve clinical outcomes following PCI in this highest-risk patient subset.\n\nCurrent guidelines recommend dual antiplatelet therapy (DAPT) consisting of aspirin and a potent P2Y12 receptor inhibitor for 12 months after primary PCI for STEMI, unless there are contraindications such as excessive risk of bleeding. A recent meta-analysis of five large-scale randomized clinical trials including a total of 32'145 patients, of whom 4,070 (12.7%) patients were treated for STEMI, indicated that 1-3 months of DAPT followed by P2Y12 inhibitor-based single antiplatelet therapy (SAPT) after second-generation DES implantation in patients with chronic and acute coronary syndromes was associated with lower risk for major bleeding and similar risk for stent thrombosis, all-cause death, myocardial infarction, and stroke compared with conventional DAPT. These findings suggest that a potent P2Y12 inhibitor-based SAPT following a short DAPT course (1-3 months) may represent a preferable treatment option, which is associated with similar ischemic, but lower bleeding risk, for patients undergoing PCI with newer-generation DES compared to standard conventional 12 months DAPT.\n\nThe question of whether SAPT using a potent oral P2Y12 inhibitor (ticagrelor or prasugrel) without aspirin (aspirin-free strategy) after primary PCI with a newest-generation thin-strut polymer-free drug-eluting stent is safe and effective compared to a conventional guideline-recommended 6- to 12-month DAPT course among patients with STEMI remains uncertain.",[26],[258,259,211,260],"Single antiplatelet therapy","P2Y12 receptor inhibitor","Polymer-free drug-eluting stent","2026-01-28",{"date":263,"type":39},"2026-01-30",{"date":265,"type":39},"2025-11-01",{"date":267,"type":20},"2028-03-01",{"name":269,"class":46},"IGLESIAS Juan Fernando",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":278,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":282,"conditions":283,"keywords":287,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":186},"100351663","cell-free-dna-in-cardiac-sarcoidosis-100351663","NCT03858777","Cell Free DNA in Cardiac Sarcoidosis","Cardiomyocyte Specific Cell Free DNA as a Marker of Cardiac Sarcoidosis","cfDNA in CS","1. Sarcoidosis patients without evidence of active myocarditis:\n\n   * Inclusion:\n\n     * Diagnosis of sarcoidosis based on the ATS\u002FERS criteria.\n     * Normal 12 lead ECG within the past one year.\n     * Non-smoker.\n     * No immunosuppressive therapy for at least one year.\n   * Exclusion:\n\n     * Known cardiac disease.\n     * Active smoker.\n     * On immunosuppressive therapy.\n2. Sarcoidosis patients with evidence of active myocarditis:\n\n   * Inclusion:\n\n     * Diagnosis of sarcoidosis based on the ATS\u002FERS criteria.\n     * Evidence of active myocarditis based on recent cMRI or cFDG-PET.\n     * Non-smoker.\n   * Exclusion:\n\n     * Known cardiac disease other than sarcoidosis.\n     * Active smoker.\n     * On immunosuppressive therapy.\n3. Acute ST elevation myocardial infarction (STEMI):\n\n   * Inclusion:\n\n     * Diagnosis STEMI based on 1mm ST elevation in 2 or more contiguous leads.\n     * Symptom onset within 12 hours.\n     * Undergoing cardiac intervention for acute coronary syndrome.\n     * Able to consent for blood draw.\n   * Exclusion:\n\n     * Active smoker.\n     * Hemodynamically unstable.\n4. Healthy controls:\n\n   * Inclusion:\n\n     * No known cardiac disease.\n     * No known cardiovascular risk factors: hypertension, diabetes.\n     * Non-smoker.",true,{"count":280,"type":20},120,[23],"Sarcoidosis is a multisystem granulomatous disease of unknown cause that can affect any organ in the body, including the heart. Granulomatous myocarditis can lead to ventricular dysfunction and ventricular arrhythmias causing significant morbidity and mortality. Immunosuppressive therapy (IST) has been shown to reverse active myocarditis and preserve left ventricular (LV) function and in some cases improve LV function. In addition, IST can suppress arrhythmias that develop due to active myocarditis and prevent the formation of scar.\n\nThe potential role of cardiac biomarkers, including brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and cardiac troponins, in detecting active myocarditis is limited and studies have been disappointing. At present, there are no biomarkers to detect active myocarditis and the use of advanced imaging modalities (FDG-PET) for assessing and monitoring active myocarditis is not feasible or practical and is associate with high radiation exposure. As such, a biomarker that is reflective of active myocarditis and that is cardiac specific will assist physicians in assessing the presence of active myocarditis to guide therapeutic decisions and to assess response to therapy which can limit further cardiac damage.\n\nCell free DNA (cfDNA) are fragments of genomic DNA that are released into the circulation from dying or damaged cells. It is a powerful diagnostic tool in cancer, transplant rejection and fetal medicine especially when the genomic source differs from the host. A novel technique that relies on tissue unique CpG methylation patterns can identify the tissue source of cell free DNA in an individual reflecting potential tissue injury. We will be conducting a pilot study to explore the utility of this diagnostic tool to identify granulomatous myocarditis in patients with sarcoidosis.",[284,285,286,26],"Sarcoidosis With Myocarditis","Sarcoidosis","Healthy",[288],"sarcoidosis","2026-01-07",{"date":291,"type":39},"2026-01-09",{"date":293,"type":39},"2019-05-01",{"date":295,"type":20},"2028-06-30",{"name":297,"class":46},"Nabeel Hamzeh",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":21,"phases":307,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":4},"100607996","phase-4-rivaroxaban-for-slow-coronary-flow-after-pci-in-stemi-100607996","NCT07195812","Rivaroxaban for Slow Coronary Flow After PCI in STEMI","Evaluation of the Efficacy and Safety of Rivaroxaban in Improving Slow Coronary Flow After Percutaneous Coronary Intervention in STEMI Patients: A Multicenter, Prospective,Randomized, Controlled Study","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of gender;\n* Patients with ST-segment elevation myocardial infarction (STEMI) (meeting the diagnostic criteria of the 2019 Chinese \"Guidelines for the Diagnosis and Treatment of Acute ST-Segment Elevation Myocardial Infarction\");\n* Patients undergoing percutaneous coronary intervention (PCI);\n* Patients with slow flow after PCI (TIMI flow grade \\> 0 but \\\u003C 3);\n* Signed informed consent form and willingness to comply with follow-up.\n\nExclusion Criteria:\n\n* Presence of malignant tumors or diseases with a life expectancy of less than 1 year;\n* Coagulation disorders, diagnosed or suspected hematological diseases (excluding mild or moderate anemia);\n* Thrombocytopenia (platelet count \\\u003C 100 × 10⁹\u002FL); history of severe gastrointestinal diseases or peptic ulcers; active bleeding within the past 3 months or major surgery history; history of intracranial hemorrhage or intracranial aneurysm;\n* History of cerebral hemorrhage or ischemic stroke within the past 6 months;\n* Patients with cardiogenic shock; systemic infections or immune system diseases; confirmed, highly suspected, or unable to rule out aortic dissection; severe uncontrolled hypertension (systolic blood pressure \\> 180 mmHg and\u002For diastolic blood pressure \\> 110 mmHg);\n* Current use of rivaroxaban or requiring long-term anticoagulation therapy (e.g., atrial fibrillation);\n* Patients with renal insufficiency (eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m²) or hepatic insufficiency (Child-Pugh Class B or C);\n* Lactating or pregnant women, or women of childbearing potential unable to use effective contraception during the study period;\n* Patients with any contraindications or allergies to rivaroxaban, aspirin, clopidogrel, or ticagrelor;\n* Participation in other clinical trials within the past 3 months;\n* Other conditions deemed unsuitable for participation by the investigator.",{"count":306,"type":20},60,[308],"PHASE4","The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban. The main questions it aims to answer are:\n\nDoes drug Rivaroxaban Reduce the Corrected TIMI Frame Count (cTFC) in 1 Week After PCI ?\n\nResearchers will compare Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) to Dual Antiplatelet Therapy to see if drug Combination therapy with rivaroxaban, aspirin works to treat Slow Flow in STEMI Patients After PCI.\n\nParticipants will:\n\nTake drug Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) or Dual Antiplatelet Therapy every day for 1 months.\n\nVisit the clinic in 7 days、30 days and 365 days for checkups and tests.",[26,311],"No-Reflow Phenomenon",[313,26,314,311,315,28],"Rivaroxaban","Slow Coronary Flow","Antiplatelet Therapy","2025-09-25",{"date":318,"type":39},"2025-09-29",{"date":320,"type":20},"2025-10",{"date":322,"type":20},"2028-05",{"name":324,"class":46},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":349,"leadSponsor":351,"locationsCount":353},"100555004","risk-characterization-of-non-culprit-vessels-in-patients-undergoing-primary-pci-for-st-elevation-mi-in-multivessel-disease-100555004","NCT06506448","Risk Characterization of Non-culprit Vessels in Patients Undergoing Primary PCI for ST-elevation MI in Multivessel Disease","Anatomical, Physiological and Inflammatory Characterization of the Non-Culprit Vessels in Patients Undergoing Primary PCI for ST-Elevation Myocardial Infarction in the Presence of Multivessel Disease Toward a Personalised Approach to Complete Revascularisation After Primary PCI","PICNIC","Inclusion Criteria:\n\n1. Ability to provide written informed consent (post PPCI)\n2. Age 18 years to 85 years\n3. Presentation of acute STEMI within 12 hours of symptom on-set\n4. Culprit artery PPCI\n5. Coronary stenosis of \\> 50% diameter stenosis by visual estimation in NIRA with a minimum diameter of 2.5mm\n\nExclusion Criteria:\n\n1. Cardiogenic shock\n2. Decompensated heart failure requiring intubation, inotropes, or intra-aortic balloon counter pulsation\n3. Refractory ventricular arrhythmia\n4. Previous coronary artery bypass surgery (CABG)\n5. Stent thrombosis and in stent restenosis\n6. An intention before inclusion into the study to revascularize a non-culprit lesion\n7. Active malignancy or inflammatory disorders such as rheumatoid arthritis or inflammatory bowel disease\n8. Severe valvular heart disease requiring surgery\n9. Planned surgical revascularisation\n10. Active participation in another study\u002Ftrial\n11. \\\u003C 12 months life expectancy\n12. Contraindication to CTCA\n\n    * Presence of internal defibrillator\n    * Known allergy to iodinated contrast\n    * Pregnancy\n    * Contraindication to intravenous beta blockade\n    * Contraindication to acute sublingual nitrate administration\n    * Mechanical prosthetic heart valve\n    * Advanced renal impairment (creatinine \\>200)\n    * Significant valve disease (sever aortic stenosis or regurgitation; severe mitral regurgitation)\n\nAngiographic exclusion criteria\n\n1. NIRA stenosis of 50% or more in the left main stem or the ostia of both the left anterior descending and circumflex arteries\n2. \\\u003C TIMI (thrombolysis in myocardial infarction) flow grade 3 in the NIRA,\n3. Evidence of thrombus in the NIRA.","85 Years",{"count":335,"type":20},320,"Most heart attacks occur because a clot forms in a coronary artery blocking blood flow. Without blood heart muscle dies. Untreated, clots can cause a specific type of heart attack -ST-elevation myocardial infarction (STEMI). STEMI patients are treated immediately by finding the blocked artery (\"culprit\" lesion) using a dye injected into the coronary arteries and then by unblocking the artery using balloons and stents. This procedure - primary angioplasty - is offered 24\u002F7 and limits the size of heart attacks and saves lives.\n\nCardiologists know how to treat STEMI patients but it's less clear what to do about narrowings in other coronary arteries (\"bystander\" disease). This is important - if they're left alone some bystander lesions can cause future events including heart attacks or angina. Recent trials compared stenting ALL the bystander narrowings after primary angioplasty, with stenting none and showed some benefit from stenting all of them (\"complete revascularisation\").\n\nHowever, complete revascularisation carries extra risk, putting patients through more complicated procedures and using up resource. A blanket strategy of complete revascularisation of ALL bystander narrowings in ALL STEMI patients is unlikely to be the correct answer as only a small minority of these patients have further events.\n\nIn PICNIC the investigators want to identify bystander narrowings most likely to cause a future event, and those unlikely to do so. The study can then test the hypothesis that only the high-risk bystander narrowings need stenting, and the others can be treated with tablets only. Investigators will study patients using specialised imaging techniques from coronary artery CT scans and levels of inflammation to see which narrowings cause future events and which do not. If this can be done, a case can be made to test complete revascularisation only in bystander narrowings that look high risk.",[26],[205,339,340,341,342,343,344],"Infarct related artery","Non-infarct related artery","Computerised Tomography Coronary Angiography CTCA","Fractional Flow Reserve from CT (FFRct)","Fat Attenuation Index (FAI)","Inflammation","2025-09-17",{"date":347,"type":39},"2025-09-23",{"date":239,"type":39},{"date":350,"type":20},"2029-01",{"name":352,"class":46},"University Hospital Southampton NHS Foundation Trust",3,{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":333,"enrollmentInfo":361,"targetDuration":4,"studyType":21,"phases":363,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":47},"100551839","phase-2-a-study-of-rtp-026-to-assess-safety-tolerability-and-efficacy-in-patients-with-st-elevation-myocardial-infarction-stemi-100551839","NCT06465303","A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)","An Exploratory, Randomised, Double-blind, Multicentre, Placebo-controlled Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)","Inclusion Criteria:\n\n* Informed consent for participation in the study has been obtained prior to initiating any study-specific procedures\n* Men between 18-85 years of age and post-menopausal women up to 85 years of age\n* Acute onset of chest pain of \\\u003C 12 hours duration\n* STEMI as characterized on ECG by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with a minimum of 1 mm concordant ST elevation or 1 mV ST elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior acute myocardial infarction (AMI)\n* Eligible for primary PCI\n* NLR in the range of 7-17 at hospital admission. In patients with chest pain lasting \\> 3 - ≤ 6 hours at admission, the NLR should be in the range of 4.8-17 and for patients with chest pain lasting ≤ 3 hours at admission, the NLR should be in the range of 4.8-17, or the neutrophile count should be ≥ 9 x 10E9\u002FL, irrespective of the lymphocyte count. For STEMI patients with an anterior or anterolateral infarction, the NLR should be ≥3.\n\nExclusion Criteria:\n\n* Participation in any other study involving investigational drug(s) during the study and within 4 weeks prior to study entry\n* Previous exposure to RTP-026\n* Time from symptoms onset to primary PCI \\> 12 hours\n* Previous CABG\n* Evidence of active malignant disease\n* Ongoing treatment with immune suppressive compounds\n* Any condition that, in the view of the investigator, would suggest that the patient is unable to comply with the study protocol and procedures\n* Known contraindications to CMR\n* ORBI Risk Score \\> 12",{"count":362,"type":20},96,[364],"PHASE2","This is an exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026.\n\nThe study population will consist of men and women with documented evidence of ST-elevation myocardial infarction (STEMI) referred to primary Percutaneous Coronary Intervention (PCI).",[26],"2025-09-16",{"date":369,"type":39},"2025-09-22",{"date":371,"type":39},"2024-07-16",{"date":373,"type":20},"2025-12-21",{"name":375,"class":376},"ResoTher Pharma","INDUSTRY",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":387,"conditions":388,"keywords":390,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":47},"100577187","assessment-of-coronary-microvascular-dysfunction-after-stemi-using-continuous-saline-thermodilution-100577187","NCT06795035","Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution","ConMicro STEMI: Assessment of Coronary Microvascular Dysfunction After ST-Elevation Myocardial Infarction Using Continuous Saline Thermodilution","ConMICRO STEMI","Inclusion Criteria:\n\n* Adults (persons \\>18 years old) presenting to Cleveland Clinic cardiac catheterization lab within 24 hours of symptom onset, with clinical and EKG findings concerning for STEMI, with intent to undergo emergent primary PCI, who have culprit artery identified on diagnostic angiography\n* Adults (persons \\>18 years old) presenting to Cleveland Clinic cardiac catheterization lab for pharmaco-invasive management of failed fibrinolysis, with intent to undergo emergent PCI, who have culprit artery identified on diagnostic angiography\n* On-call treating interventional cardiologist is trained in the method of continuous saline thermodilution for coronary microvascular assessment\n\nExclusion Criteria:\n\n* No evidence of coronary obstruction on diagnostic angiography (e.g., Takotsubo, myocarditis leading to STEMI activation).\n* Patients in hemodynamic shock\n* Culprit artery \\\u003C3.0 mm in diameter.\n* Culprit artery being a bypass graft\n* Patients physically unable to tolerate additional time required to conduct coronary microvascular testing after primary PCI.\n* Patients with eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2 are excluded from contributing cardiac MRI data\n* Patients with standard contraindications to CMR (e.g., pacemakers, cochlear implants, certain prosthetic heart valves, certain surgical implants) are excluded from contributing cardiac MRI data\n* Unable to provide verbal and written consent\n* Pregnancy",{"count":386,"type":20},70,"The goal of this observational study to measure the heart's microvascular function in the setting of a myocardial infarction (MI), or heart attack, using a method called continuous saline thermodilution (CST). The participants will include people who are experiencing MI from sudden and complete blockage of a coronary artery requiring immediate balloon and\u002For stent therapy. After getting the balloon and\u002For stent therapy, participants will have their heart's microvascular system tested using CST. The main questions it aims to answer are:\n\n* What measurements using CST can we expect from the heart's microvascular system during a treated MI?\n* Can CST measurements during a treated MI predict the amount of heart muscle that is injured and that recovers?\n\nFor this study, participants will undergo measurement of their heart's microvascular function after balloon and\u002For stent therapy for the MI. They will then receive an MRI scan of the heart several days after the MI.",[26,27,389],"Microvascular Obstruction",[62,391,392,393,394],"Microvascular","MVO","MRR","Thermodilution","2025-07-29",{"date":397,"type":39},"2025-07-31",{"date":399,"type":39},"2025-05-29",{"date":401,"type":20},"2027-12-31",{"name":403,"class":46},"The Cleveland Clinic",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":411,"enrollmentInfo":412,"targetDuration":4,"studyType":21,"phases":413,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":47},"100597466","the-effect-of-low-level-tragus-stimulation-on-echocardiographic-parameters-in-patients-with-st-segment-elevation-myocardial-infarction---a-single-centre-randomized-control-trial-100597466","NCT07058857","The Effect of Low-Level Tragus Stimulation on Echocardiographic Parameters in Patients With ST-Segment Elevation Myocardial Infarction - A Single-Centre Randomized Control Trial","ELITE-STEMI","Inclusion Criteria:\n\n* Onset STEMI less than 12 hours\n* Participant agreed to be included in this study\n* Killip class I - II on presentation\n* SBP \\>90 mmHg and\u002For MAP \\>65 mmHg\n* Sinus rhtyhm\n\nExclusion Criteria:\n\n* History of myocardial infarction, stroke, heart failure with reduce ejection fraction, chronic total occlussion on prior coronary angiography, chronic kidney disease (eGFR \\\u003C 30) or on hemodyalisis, malignancy, hematology disease, autoimmune, or other chronic diseases\n* On permanent pacemaker\n* Acute infection\n* Pregnant woman","75 Years",{"count":19,"type":20},[23],"The goal of this clinical trial is to learn the effect of low level tragus stimulation (LLTS) on echocardiographic parameter in patient with ST-segment Elevation Myocardial Infarction (STEMI) who undergo primart percutaneous coronary intervention (PPCI). It will also learn about the safety of LLTS in such setting. The main questions, it aims to answer are compared with sham control:\n\nDoes LLTS could alter left ventricular ejection fraction in patients with STEMI? Does LLTS could alter wall motion score index in patients with STEMI? Does LLTS could alter diastolic dysfunction in patients with STEMI?\n\nResearchers will compare LLTS to sham LLTS control to see if LLTS have benefit in participants with STEMI participants will divided into two group i.e. treatment group vs control (sham\u002Fplacebo) group..\n\nBoth groups undergo transthoracal echocardiographi examination before and after PPCI..",[26],[211,417,418,419],"Low level tragus stimulation","Left ventricular ejection fraction","Wall motion score index","2025-06-30",{"date":422,"type":39},"2025-07-10",{"date":424,"type":39},"2025-01-01",{"date":426,"type":20},"2025-09-30",{"name":428,"class":46},"Universitas Diponegoro",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":333,"enrollmentInfo":436,"targetDuration":4,"studyType":21,"phases":438,"briefSummary":439,"conditions":440,"keywords":444,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":450,"leadSponsor":452,"locationsCount":454},"100434641","crp-apheresis-in-stemi-100434641","NCT04939805","CRP Apheresis in STEMI","Selective C-reactive Protein Apheresis in ST-elevation Myocardial Infarction","Inclusion Criteria:\n\n1. Diagnosis of first acute STEMI in accordance with the European Society of Cardiology (ESC) Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation\n2. Symptoms consistent with STEMI with beginning greater than 30 minutes but less than 12 hours prior to primary percutaneous coronary intervention (PCI)\n3. CRP elevation of ≥7 mg\u002Fl measured between 6 to 16 hours after primary PCI\n4. Eligible for primary PCI\n5. Age ≥18 years\n6. Written informed consent\n\nExclusion Criteria:\n\n1. Prior acute myocardial infarction, coronary artery bypass surgery or PCI.\n2. Persistent hemodynamic instability (Killip class \\>2 including cardiogenic shock) or resuscitated cardiac arrest not allowing a CMR scan.\n3. The patient is febrile (temperature \\>38°C) or has experienced an acute infection with fever in the last 14 days.\n4. CRP \\>15 mg\u002Fl at time of hospital admission.\n5. Chronic inflammatory disease.\n6. Known history of severe hepatic failure\n7. Chronic kidney disease with a creatinine clearance \\\u003C30ml\u002Fmin.\u002F1.73m²\n8. Contraindication to CMR.\n9. Pre-STEMI life expectancy of \\\u003C1 year\n10. Participation in another interventional trial\n11. Limited possibility to join the follow-up examinations (e.g. patient lives abroad)\n12. Pregnancy",{"count":437,"type":20},202,[23],"Background: In patients with acute ST-elevation myocardial infarction (STEMI), the amount of infarcted myocardium (infarct size) is known to be a major predictor for adverse remodeling and recurrent adverse cardiovascular events. Effective cardio-protective strategies with the aim of reducing infarct size are therefore of great interest. Local and systemic inflammation influences the fate of ischemic myocardium and thus, adverse remodeling and clinical outcome. C-reactive protein (CRP) also acts as a potential mechanistic mediator that adversely affects the amount of irreversible myocardial tissue damage after acute myocardial infarction.\n\nObjective: The main objectives of the current study are to investigate the efficacy of selective CRP apheresis, using the PentraSorb®-CRP system, as an adjunctive therapy to standard of care for patients with acute STEMI treated with primary PCI.\n\nDesign: Investigator-initiated, prospective, randomized, open-label (outcome assessors masked), controlled, multicenter, two group trial with a two-stage adaptive design.\n\nInnovation: Selective CRP apheresis offers potential to decrease infarct size and consequently improve outcome after PCI for STEMI. This is the first randomized trial investigating the impact of selective CRP apheresis on infarct size in post-STEMI patients. In perspective, the study design allows furthermore to collect robust evidence for the design of a definitive outcome study.",[26,441,442,443],"C-Reactive Protein","Apheresis","Myocardial Injury",[445],"Cardiac magnetic resonance imaging","2025-05-06",{"date":448,"type":39},"2025-05-09",{"date":124,"type":39},{"date":451,"type":20},"2025-08-31",{"name":453,"class":46},"Medical University Innsbruck",5,{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":186},"100557237","clinical-characteristics-and-outcomes-among-stemi-patients-with-cardiogenic-shock-at-abu-dhabi-city-100557237","NCT06535503","Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City","Clinical Characteristics and Outcomes Among ST-elevation Myocardial Infarction (STEMI) Patients With Cardiogenic Shock at Abu Dhabi City","Inclusion Criteria:\n\n* Age more than 18.\n* STEMI complicated by cardiogenic shock.\n* Were hospitalized or treated at SSMC or SKMC for STEMI complicated by cardiogenic shock.\n* Patient admitted between January 2019 to March 2024.\n\nExclusion Criteria:\n\n* Age less than 18.\n* Shock patient not related to Myocardial infarction.\n* NSTEMI-related cardiogenic shock.\n* Patients who were not treated at SSMC or SKMC for the STEMI complicated by cardiogenic shock.\n* Patient not admitted between January 2019 to March 2024.",{"count":463,"type":20},400,"A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during their hospital stay for two tertiary hospitals in Abu Dhabi, UAE, from 2020-2024.",[26,466],"Cardiogenic Shock",[62,466,468,469],"Morbidity","Mortality","2025-02-13",{"date":472,"type":39},"2025-02-17",{"date":474,"type":39},"2024-07-01",{"date":476,"type":20},"2025-05-30",{"name":478,"class":479},"Abu Dhabi Health Services Company","OTHER_GOV",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":21,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":47},"100532683","treatment-of-acute-coronary-syndromes-with-low-dose-colchicine-100532683","NCT06215989","Treatment of ACuTe Coronary Syndromes With Low-dose colchICine","Treatment of ACuTe Coronary Syndromes With Low-dose colchICine (TACTIC): a Randomised, Double-blinded, Placebo-controlled, Multicentric Trial","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Definite diagnosis of ACS;\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Type 2 myocardial infarction (Patients with symptoms or signs of myocardial ischemia and evidence of increased oxygen demand or decreased supply \\[for example, tachyarrhythmia, hypotension, or anaemia\\] secondary to an alternative pathology and myocardial necrosis are defined as suffering type 2 myocardial infarction. The classification of type 2 myocardial infarction also includes patients with coronary vasospasm, embolism or spontaneous dissection without evidence of atherothrombosis related to coronary artery disease);\n* Valvular heart disease that is considered likely to require surgical intervention;\n* History of non-skin cancer in the past 3 years;\n* Inflammatory bowel disease or chronic diarrhea;\n* History of gastric ulcer or previous gastric bleeding;\n* Neuromuscular diseases or non-transient (At least 2 laboratory tests) creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction);\n* Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities(Hemoglobin \\\u003C100g\u002FL or hematocrit \\\u003C 30% or \\> 52% or white blood cell count \\\u003C 3×109\u002FL or platelet count \\\u003C 100×109\u002FL);\n* Estimated glomerular filtration rate (eGFR)\\\u003C30mL\u002Fmin\u002F1.73m2 (based on CKD-EPI formula);\n* Serum alanine aminotransferase and\u002For aspartate aminotransferase levels greater than 2 times the upper limit of the normal range accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders(INR\\>1.5)(except for elevated glutamic oxalacetic transaminase associated with myocardial infarction);\n* Decline in cognitive function due to inability to perform basic activities of daily living independently;\n* Drug or alcohol abuse;\n* Other immunosuppressive therapies already in existence or planned;\n* Other causes require long-term colchicine treatment;\n* History of clear or suspected colchicine allergy;\n* Strong CYP3A4 or P-glycoprotein inhibitors (such as cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) have been used and no other alternative drugs can be used.",{"count":488,"type":20},6574,[23],"This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary syndromes (ACS) through a prospective, randomized, double-blind, placebo-controlled clinical trial.",[492,493,26,494,495],"Acute Coronary Syndrome","Unstable Angina","Non ST Segment Elevation Myocardial Infarction","Colchicine","2024-10-27",{"date":498,"type":39},"2024-10-30",{"date":500,"type":39},"2024-09-02",{"date":502,"type":20},"2028-06",{"name":504,"class":46},"Beijing Anzhen Hospital",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":411,"enrollmentInfo":513,"targetDuration":4,"studyType":21,"phases":515,"briefSummary":516,"conditions":517,"keywords":518,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":527,"locationsCount":529},"100470827","phase-4-efficacy-and-safety-of-a-half-dose-bolus-of-r-sak-prior-to-primary-pci-in-st-elevation-myocardial-infarction-100470827","NCT05410925","Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction","Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction: a Multicenter Randomized Double-blind Placebo-controlled Trial (OPTIMA-6)","OPTIMA-6","Inclusion Criteria:\n\n1. Age 18-75 years, weight ≥45 kg\n2. Diagnosed as STEMI (meeting the following two conditions simultaneously)\n\n   1. Ischemic chest pain lasts ≥ 30 minutes\n   2. ECG indicates that ST-segment elevation of two or more contiguous precordial leads ≥ 0.1 mV, or ST-segment elevation of two or more contiguous precordial leads ≥ 0.2 mV\n3. Time from onset of persistent chest pain to randomization ≤12 hours\n4. Primary PCI expected to be performed ≥30 minutes, and ≤120 minutes\n\nExclusion Criteria:\n\n1. Cardiogenic shock\n2. Active bleeding or known at high risk of bleeding (including grade Ⅲ or Ⅳ retinopathy or retinal gastrointestinal or urinary tract hemorrhage within the past 1 month)\n3. Ischemic stroke or TIA in the past 6 months\n4. History of hemorrhagic stroke\n5. Known intracranial aneurysm\n6. Severe trauma, surgery or head injury within 1 month\n7. Suspected aortic dissection or infective endocarditis\n8. Puncture with difficult hemostasis by compression within 1 month (e.g., visceral biopsy, compartment puncture)\n9. Currently taking anticoagulants\n10. Poorly controlled hypertension ( ≥180\u002F110 mmHg)\n11. Severe hepatic or renal impairment indicated by the consultation or previous history (glutamic-pyruvic transaminase or glutamic oxalacetic transaminase \\>3 times upper limit of normal value; eGFR \\\u003C15 ml\u002Fmin\u002F1.73m\\^2, calculated based on CKD-EPI)\n12. Known allergy to r-SAK\n13. Pregnancy, lactation, or planning for pregnancy\n14. History of chronic total occlusion, myocardial infarction or CABG\n15. Having taken antiplatelet drugs other than aspirin and ticagrelor, such as clopidogrel, prasugrel or cilostazol after the symptom onset\n16. Patients with other conditions that made them unsuitable to be recruited at the discretion of the investigators",{"count":514,"type":20},2260,[308],"As an effective treatment for acute ST-segment elevation myocardial infarction (STEMI), early reperfusion may reduce the infarct size and improve the prognosis of patients. However, it remains uncertain whether adjunctive thrombolytic therapy administered immediately prior to primary percutaneous coronary intervention (PCI) improves outcomes in patients undergoing the procedure within 120 minutes.\n\nIn this investigator-initiated, prospective, multi-center, randomized, double-blind, placebo-controlled trial, subjects meeting the inclusion\u002Fexclusion criteria should be randomly assigned 1:1 to the trial group (r-SAK) or the control group (placebo). The risk of major adverse cardiovascular events within 90 days will be observed.",[26],[26,519,520],"Recombinant Staphylokinase","Thrombolysis","2024-10-24",{"date":523,"type":39},"2024-10-28",{"date":525,"type":39},"2023-04-08",{"date":401,"type":20},{"name":528,"class":46},"The First Affiliated Hospital with Nanjing Medical University",61,{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":16,"minAge":82,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":21,"phases":540,"briefSummary":541,"conditions":542,"keywords":543,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":186},"100501723","ivus-versus-ffr-for-non-infarct-related-artery-lesions-in-patients-with-multivessel-disease-and-acute-mi-100501723","NCT05812963","IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute MI","Randomized Controlled Trial of Intravascular Ultrasound Versus Fractional Flow Reserve for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute Myocardial Infarction","FRAME-AMI2","Inclusion Criteria:\n\n* Subject must be at least 19 years of age\n* Acute ST-segment elevation myocardial infarction (STEMI)\n\n  \\*STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block\n* Acute non-ST-segment elevation myocardial infarction (NSTEMI)\n\n  \\*NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:\n  1. Symptoms of ischemia.\n  2. New or presumed new significant ST-T wave changes\n  3. Development of pathological Q waves on electrocardiography.\n  4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.\n  5. Intracoronary thrombus detected on angiography.\n* Successful primary percutaneous coronary intervention (PCI) in \\\u003C 12 h after the onset of symptoms for STEMI patients (In case of NSTEMI, PCI should be performed within 72 hours of symptom onset)\n* Multivessel disease (at least one stenosis of \\>50% in a non-IRA ≥2.25 mm by visual estimation)\n* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Non-IRA stenosis not amenable for PCI treatment by operators' decision\n* Cardiogenic shock (Killip class IV) already at presentation or the completion of IRA PCI\n* Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus\n* Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)\n* Pregnancy or breast feeding\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C2 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n* Other primary valvular disease with severe degree: severe mitral regurgitation, mitral stenosis, severe aortic regurgitation, or aortic stenosis\n* Unwillingness or inability to comply with the procedures described in this protocol.",{"count":539,"type":20},1400,[23],"The aim of the study is to compare clinical outcomes between intravascular ultrasound (IVUS)-guided treatment decision versus fractional flow reserve (FFR)-guided treatment decision for non-infarct related artery stenosis in patients with acute myocardial infarction (AMI) and multivessel disease.",[26,176],[90,544,545,546,547,176],"Fractional flow reserve","intravascular ultrasound","Multivessel disease","Complete revascularization","2024-10-22",{"date":521,"type":39},{"date":551,"type":39},"2023-09-18",{"date":553,"type":20},"2029-12-31",{"name":555,"class":46},"Samsung Medical Center",{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":21,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":454},"100515089","safety-of-ticagrelor-monotherapy-after-primary-percutaneous-coronary-intervention-for-st-elevation-myocardial-infarction-and-the-effect-on-intramyocardial-haemorrhage-100515089","NCT05986968","Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage","STOP-IMH","Inclusion Criteria:\n\n* Clinical and electrocardiographical diagnosis of STEMI\n* Successful PCI (according to the treating physician) of the infarct-related vessel with a modern drug-eluting stent (DES)\n\nExclusion Criteria:\n\n* Known allergy or contraindication for aspirin, ticagrelor or prasugrel.\n* Previous PCI or MI less than 12 months ago\n* Previous cardiac surgery\n* Participation in another clinical cardiology study or study concerning platelet aggregation\u002F thrombosis. (unless the antithrombotic therapy prescribed in this other study will end due to clinical reasons (e.g. the STEMI))\n* Pregnancy and breast feeding\n* Concurrent use of oral anticoagulants (OAC)\n* The periprocedural use of GPIIb\u002FIIIa inhibitors\n* Planned surgical intervention within 12 months of PCI\n* Creatinine clearance \\\u003C30mL\u002Fmin or dialysis\n* PCI of stent thrombosis\n* Suboptimal stent result as judged by the interventional cardiologist.\n* Life expectancy shorter than 13 months.\n* Contra-indications for MRI or unable to undergo MRI (only applicable for the CMR subgroup population).",{"count":564,"type":20},200,[23],"The main goal of this clinical trial is to assess whether direct omission of aspirin after Percutaneous Coronary Intervention (PCI) with the continuation of ticagrelor monotherapy for 12 months versus 12 months ticagrelor plus aspirin is equally safe regarding the incidence of ischemic events in patients with ST elevation myocardial infarction (STEMI). Furthermore, the two treatment strategies will be compared regarding the incidence and extent of intramyocardial haemorrhage (IMH) and infarct size in the first week after PCI as determined with Cardiac Magnetic Resonance (CMR). The secondary efficacy endpoint consists of clinical bleeding events and all-cause mortality. The main analyses will comprise of clinical outcomes in the first three months after primary PCI and of CMR results. In addition, we will report on clinical outcomes at thirteen months.",[26],"2024-09-20",{"date":570,"type":39},"2024-09-23",{"date":572,"type":39},"2023-07-06",{"date":574,"type":20},"2025-12-01",{"name":576,"class":46},"Radboud University Medical Center",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":16,"minAge":584,"maxAge":411,"enrollmentInfo":585,"targetDuration":4,"studyType":21,"phases":587,"briefSummary":588,"conditions":589,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":47},"100527455","phase-2-evaluate-the-efficacy-and-safety-of-allogeneic-umbilical-cord-mesenchymal-stem-cells-as-an-add-on-treatment-for-acute-st-elevation-myocardial-infarction-stemi-patients-100527455","NCT06147986","Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells As an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients","A Phase IIa, Dose-Escalation Followed by Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells As an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients","Inclusion Criteria:\n\n1. Male or female subjects are aged ≥ 20, \\\u003C 76 years old on date of consent\n2. Presence of typical ischemic chest pain within 12 hours after symptoms onset and clinical diagnosis of acute STEMI according to the 2013 American College of Cardiology (ACC) Foundation\u002F American Heart Association (AHA) guideline for the Management of STEMI\n3. Has undergone standard-of-care for STEMI; the immediate reperfusion management should include primary percutaneous coronary intervention (PCI), aspiration thrombectomy and adjunctive antithrombotic therapy within 12 hours after the onset of symptoms\n4. Received successful acute reperfusion therapy (residual stenosis visually \\\u003C 50% and thrombolysis in myocardial infarction flow ≥ 2) with placement of an intracoronary stent and having a patent infarct-related artery suitable for cell infusion to the target area of abnormal wall motion following myocardial infarction\n5. Evidence of LVEF ≥ 30% and \\\u003C 50% diagnosed by echocardiogram\n6. Evidence of stable vital signs prior to IC infusion of UMSC01 (Day 1), defined as no clinical significance of abnormal respiration, afebrile as judged by the investigator, systolic pressure ≥ 90 mmHg and \\\u003C 160 mmHg, heart rate \\> 50\u002Fmin and \\\u003C 110\u002Fmin\n7. Adequate pulmonary function test defined as a force expiratory volume 1 second (FEV1) \\> 50% predicted and peripheral artery oxygen saturation ≥ 95% at room air\n8. Adequate hematopoietic function at the screening and before administration of study medication:\n\n   * Platelets ≥ 100,000 counts\u002FμL.\n   * Hemoglobin ≥ 8 g\u002FdL.\n   * PT, APTT ≤ 1.5X upper limit of normal (ULN).\n9. Has signed and dated informed consent\n10. All male subjects and female subjects with child-bearing potential (between puberty and 2 years after menopause) should use appropriate contraception method(s) shown below, for at least 1 year after the last UMSC01 treatment a. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception) b. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment c. Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject d. Combination of any two of the following listed methods: (d.1+d.2 or d.1+d.3, or d.2+d.3): d.1 Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \\\u003C 1%), for example hormone vaginal ring or transdermal hormone contraception d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS) d.3 Barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fvaginal suppository\n\nExclusion Criteria:\n\n1. With cardiogenic shock (defined as systolic blood pressure \\\u003C80mmHg requiring vasopressors, intra-aortic balloon pump(IABP) or extracorporeal membrane oxygenation (ECMO)\n2. Presence of severe aortic stenosis or regurgitation according to the recommendation of the 2020 ACC\u002FAHA guideline for themanagement of patients with valvular heart disease\n3. Presence of severe mitral stenosis or regurgitation according to the recommendation of the 2020 ACC\u002FAHA guideline for the management of patients with valvular heart disease\n4. With a need to undergo staged coronary intervention therapy or coronary artery bypass grafting (CABG) surgery\n5. Under an immuno-compromised condition, with known clinically significantly autoimmune conditions, or receiving immunosuppressive treatments within 12 weeks prior to the study intervention\n6. Presence of any active malignancy that required treatment within 2 years prior to Screening Visit\n7. With ongoing or within the past 2 years serious medical conditions (e.g., concurrent illness), other clinically significant cardiovascular diseases, psychiatric condition (e.g., alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigators' opinion could interfere with the results of the trial or adversely affect the safety of the subject\n8. With inadequate hepatic and renal function after onset of STEMI: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 4 x upper limit of normal (ULN); estimated glomerular filtration rate (eGFR) \\\u003C 40 mL\u002Fmin, calculated by Modification of Diet in Renal Disease equation (MDRD) 175 formula\n9. With uncontrolled diabetes mellitus (blood glucose level \\> 200 mg\u002FdL or HbA1c ≥ 8.5%)\n10. Participation in a clinical trial of an investigational product within 3 months prior to Screening Visit\n11. Known or suspected hypersensitivity or previous adverse reaction to any ingredients of study product\n12. Female subject with child-bearing potential (between puberty and 2 years after menopause) who is pregnant, lactating or has positive urine pregnancy test at Screening Visit\n13. Subjects not suitable to participate the trial as judged by the Investigator(s)","20 Years",{"count":586,"type":20},41,[364],"This phase IIa study is to identify the efficacy and safety of IC(intracoronary) and IV(Intravenous) administrations of UMSC01 in patients with STEMI . This product is a new cell therapy product for treating AMI and produced by Ever Supreme Bio Technology Co., Ltd in Taiwan. The previous Phase I, open-label, single arm, single center study was conducted to evaluate the safety and to explore the efficacy of UMSC01 in subjects with STEMI via intracoronary administration followed by intravenous infusion. This first-in-human Phase I study of UMSC01 was completed on August 2nd, 2021. Among 8 subjects enrolled, no subjects experienced treatment-related TEAEs.",[26],"2024-09-10",{"date":592,"type":39},"2024-09-19",{"date":594,"type":39},"2023-09-24",{"date":596,"type":20},"2027-06-24",{"name":598,"class":376},"Ever Supreme Bio Technology Co., Ltd.",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":605,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":21,"phases":608,"briefSummary":609,"conditions":610,"keywords":611,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":47},"100557397","the-efficacy-and-safety-of-low-level-tragus-stimulation-on-heart-rate-variability-neutrophil-lymphocyte-ratio-and-major-adverse-cardiovascular-events-in-patients-with-st-segment-elevation-myocardial-infarction-tesla-stemi-100557397","NCT06537583","The Efficacy and Safety of Low-Level Tragus Stimulation on Heart Rate Variability, Neutrophil-Lymphocyte Ratio, and Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction (TESLA-STEMI)","The Efficacy and Safety of Low-Level Tragus Stimulation on Heart Rate Variability, Neutrophil-Lymphocyte Ratio, and Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction","TESLA-STEMI","70 Years",{"count":19,"type":20},[23],"The goal of this clinical trial is to learn the effect of low level tragus stimulation (LLTS) on heart rate variability (HRV), neutrophil-lymphocyte ratio, and major adverse cardiovascular events in patient with ST-segment Elevation Myocardial Infarction (STEMI). It will also learn about the safety of LLTS in such setting. The main questions, it aims to answer are compared with sham control:\n\n1. Does LLTS could alter low frequency\u002Fhigh frequency ratio in patients with STEMI?\n2. Does LLTS could alter neutrophil-lymphocyte ratio in patients with STEMI?\n3. Does LLTS could decrease mortality in patients with STEMI?\n4. Does LLTS could decrease reinfarction event in patients with STEMI?\n5. Does LLTS could decrease stroke event in patients with STEMI?\n6. Does LLTS could decrease lethal arrhythmia event in patients with STEMI?\n7. Does LLTS could decrease acute lung oedema event in patients with STEMI?\n8. Does LLTS could decrease cardiogenic shock event in patients with STEMI?\n\nResearchers will compare LLTS to sham LLTS control to see if LLTS have benefit in participants with STEMI participants will divided into two group i.e. treatment group vs control (sham\u002Fplacebo) group, then both of them:\n\n1. Undergo laboratory examination before Primary Percutaneous Coronary Intervention (PPCI)\n2. Undergo HRV measurement using WeCardio device before Primary Percutaneous Coronary Intervention (PPCI)\n3. Undergo LLTS (treatment group will have stimulation) for 60 minutes, however, sham control will not have stimulation, before PPCI\n4. Undergo PPCI\n5. Undergo laboratory examination after Primary Percutaneous Coronary Intervention (PPCI)\n6. Undergo HRV measurement using WeCardio device after Primary Percutaneous Coronary Intervention (PPCI)",[26],[612,417,613,614,615],"ST segment elevation myocardial infarction","Heart rate variability","Neutrophil-lymphocyte ratio","Major adverse cardiovascular events","2024-07-31",{"date":618,"type":39},"2024-08-05",{"date":620,"type":39},"2024-01-01",{"date":622,"type":20},"2024-09-30",{"name":428,"class":46},{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":47},"100554137","european-survey-of-cardiovascular-disease-prevention-diabetes-and-chronic-kidney-disease-euroaspire-vi-100554137","NCT06495177","European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease (EUROASPIRE VI)","European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease","EUROASPIRE VI","Inclusion Criteria:\n\n* Patients having signed an informed Consent\n* Patients aged from 18 years old at the time of identification\n* At least six and at most 24 months elapsed between the index event (the recruiting diagnostic or treatment criteria below) and the date of interview\n* Patients meeting the recruiting diagnostic or treatment criteria:\n* Coronary patients: Acute coronary events (acute coronary syndrome {STEMI or NSTEMI}, unstable angina) or an emergency or elective revascularisation for coronary artery disease (CABG, PCI)\n* High cardiovascular disease (CVD) risk patients: patients free of CVD, who have been prescribed one or more of the following treatments: blood pressure and\u002For lipid-lowering and\u002For glucose lowering (diet and\u002For hypoglycaemic agents and\u002For insulin)\n\nExclusion Criteria:\n\n* Patients living outside defined geographical areas\n* Patients admitted to hospital from outside the geographical area or under the care of cardiologists in hospitals that do not participate in EUROASPIRE VI",{"count":633,"type":20},8000,"The goal of this observational study is to provide a unique European picture of preventive action by cardiologists, other specialists and primary care physicians looking after patients with coronary heart disease (CHD), individuals at high cardiovascular disease risk and all those with hypertension, dyslipidaemia (including familial hypercholesterolaemia), diabetes and dysglycaemia and chronic kidney disease (CKD) and determine whether the European guidelines on cardiovascular disease prevention, hypertension, lipids, diabetes and chronic kidney disease are being followed.",[636,492,493,26,176],"Coronary Disease","2024-07-02",{"date":639,"type":39},"2024-07-10",{"date":641,"type":39},"2024-06-07",{"date":643,"type":20},"2029-12",{"name":645,"class":646},"European Society of Cardiology","NETWORK",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":278,"sex":16,"minAge":17,"maxAge":411,"enrollmentInfo":654,"targetDuration":4,"studyType":21,"phases":656,"briefSummary":658,"conditions":659,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":668,"leadSponsor":670,"locationsCount":47},"100542142","early-phase-1-oct-or-angiography-guided-de-escalation-of-dapt-100542142","NCT06339021","OCT or Angiography Guided De-escalation of DAPT","Evaluation of Neointimal Coverage After Guiding De-escalation of Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention by Optical Coherence Tomography or Angiography of STEMI Patients","Inclusion Criteria:\n\n1. 18 \\~ 85 years old adult patients;\n2. Patients diagnosed with STEMI and undergoing PCI.\n3. Patients able and willing to give written informed consent and to comply with the requirements of this study protocol.\n\nExclusion Criteria:\n\n1. Prior history of intracranial hemorrhage or ischemic stroke during the past 6 months；\n2. Allergy to aspirin or clopidogrel or ticagrelor;\n3. Occurrence of major adverse cardiovascular event (MACE) within 30 days after undergoing PCI;\n4. Platelet count \\\u003C 50 × 109\u002FL;\n5. Major bleeding during the past 12 months;\n6. Any form of oral, long-term anticoagulation therapy;\n7. Pregnancy or lactation;\n8. Suspected aortic dissection;\n9. Coronary CT-negative patients;\n10. Life expectancy \\\u003C1 year;\n11. Uncontrolled hypertension, systolic blood pressure (SBP) ≥180 mmHg, and\u002For diastolic blood pressure (DBP) ≥110 mmHg;\n12. Comorbid conditions included the presence of any of the following: cardiogenic shock, chronic congestive heart failure with NYHA classes III or IV, left ventricular ejection fraction (LVEF) \\\u003C 35% at transthoracic echocardiography, hypotension with SBP \\\u003C 90mmHg and\u002For DBP \\\u003C 60mmHg, severe arrhythmia (including high-degree AV block, sick sinus syndrome, sustained ventricular tachycardia), severe pulmonary insufficiency, pulmonary embolism, hepatic insufficiency due to non-cardiac causes (ALT or AST more than three times the upper limit of the institution's normal reference ranges), cirrhosis, severe renal failure (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m2);\n13. Surgery plan within 30 days;\n14. Psychiatric abnormalities or alcohol dependence;\n15. Patients who are participating in other clinical trials;\n16. Unable to tolerate 1 month of DAPT;\n17. Angiographic triple vessel disease coronary disease;\n18. Other situations judged by the investigators not to be suitable for the clinical trial.",{"count":655,"type":20},80,[657],"EARLY_PHASE1","Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus. In addition, the incorporation of the MLD MAX algorithm into daily practice guides an efficient and easily-memorable workflow for optimized OCT-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Regarding the antithrombotic therapy after revascularization, the 2023 ESC guidelines recommend the P2Y12 receptor inhibitor de-escalation (i.e. switching from ticagrelor to clopidogrel) in ACS patients may be considered as an alternative strategy to the default treatment regimen in order to reduce the risk of bleeding events.\n\nBased on the above conclusions, we designed a single-center, prospective, randomized controlled, exploratory study trial to evaluate whether the utility of OCT for guiding PCI with DES followed by antiplatelet de-escalation therapy could further reduce the stent-induced intimal hyperplasia of STEMI patients after stent implantation.",[660,661,662,663,26],"Optical Coherence Tomography","Dual Antiplatelet Therapy","Antiplatelet De-escalation","Neointimal Coverage","2024-03-24",{"date":666,"type":39},"2024-04-01",{"date":666,"type":20},{"date":669,"type":20},"2026-12-01",{"name":671,"class":46},"Shenyang Northern Hospital"]